Objective. To evaluate driving performance, cognition, and balance in patients with chronic nonmalignant pain before and after the addition of transdermal fentanyl to their treatments.
Introduction
O pioid medications are often used in the treatment of intractable nonmalignant pain conditions. The goals of treatment with opioids are to reduce pain, increase function, and promote an increased quality of life. However, side effects of opioids, such as sedation and mental clouding, have the potential to impair functioning and interfere with the goals of treatment. The impact of these side effects, including their effects on driving ability and cognition, is an issue often raised by patients at the initiation of treatment.
Physicians must weigh the risks and benefits of treatment with opioids and provide advice about whether or not to proceed. At times, a decision is made not to proceed with opioids because of side effects. From a societal perspective, the decision to use or not to use opioids has a potential impact on public welfare. Questions of whether patients treated with opioids should or should not drive are relevant for various regulatory agencies. Most physicians are required by the government to report patients who are deemed unfit to drive. The lack of empirical evidence to guide decisions poses a potential danger to patients and to others.
A limited number of empirical studies have addressed the effects of long-acting opioids on driving and cognition for patients with nonmalignant pain. These studies have been limited by the lack of proper control groups. Some investigators compared patients with nonmalignant pain conditions who were taking opioids with control groups of healthy volunteers [1] [2] [3] . For the most part, results of those studies show no significant differences between patients and healthy volunteers on cognitive measures of attention, psychomotor speed, and reaction time. Where differences do occur, they tend to be slight and/or only occur in high performance ranges (e.g., the 90th percentile). Byas-Smith et al. (unpublished data cited in [2] ) compared three groups: Patients with chronic pain on opioids, patients with chronic pain not on opioids, and healthy volunteers. No significant differences between groups were found in measures of attention, reaction time, and driving errors. Patients with chronic pain conditions, whether or not they were taking opioids, had similar scores on one test of psychomotor speed and were slower on that test than healthy controls. Therefore, those investigators concluded that the presence of chronic pain can influence the results of this measure, and that healthy volunteers are not a good control group for studying the impact of opioids on patients with chronic pain [2] . The results of those studies mirror studies in cancer patients that used healthy volunteers as controls [4, 5] .
Another study used patients who had experienced a cerebrovascular accident, traumatic brain injury, or anoxia as the control group to measure the effects of opioids on driving [6] . This group was characterized as "cerebrally compromised." Galski et al. [6] compared 16 chronic pain patients on opioids with cerebrally compromised individuals. The cerebrally compromised control group was divided into two groups: Individuals who passed a driving test (N = 162) and those who did not pass a driving test (N = 165). Results of multiple measures of cognition and driving simulation found few differences between patients with chronic pain and cerebrally compromised individuals who passed a driving test. Differences between these two groups favored better performance for patients taking opioids. Cerebrally compromised individuals who did not pass a driving test scored worse on all measures than the other two groups. The assumption in that study was that patients taking opioids would have cognitive deficits similar to those in patients with brain injuries.
Patients with nonmalignant pain conditions were used as their own controls in two studies of cognition and opioids that did not include driving measures. Haythornthwaite et al. [7] compared performance on cognitive tests for 19 patients with chronic pain conditions taking short-acting opioids before and after being titrated to morphine or methadone to achieve a 50% reduction in pain intensity. This group took an average short-acting morphine equivalent of 22.8 mg and was titrated to an average long-acting morphine equivalent of 111 mg over approximately 5 months. Patients demonstrated no decrement in cognitive functioning over the treatment period, and scores on a task of sustained attention and psychomotor speed improved over that time. These results were compared with a "usual care" group (N = 10) that took an average short-acting morphine equivalent/day of 17 mg at baseline and 19 mg at follow-up over a period of 3 months. No differences were found over the testing period between these groups. That study showed that the addition of a long-acting opioid did not result in lower functioning compared with the usual care group, and performance improved on one measure.
Moulin et al. [8] conducted a crossover design study in which patients with chronic musculoskeletal, myofascial, or rheumatologic pain were titrated to up to 60 mg of controlled-release oral morphine twice a day over a 3-week period. Patients were treated for 6 weeks with morphine or placebo (benztropine up to 1.0 mg twice per day) and washed out over a 2-week period. No differences were found between study periods on a cognitive screening test that included measures of memory, language, attention, and planning. Although the crossover design used in that study was an improvement over some previous study designs, the cognitive measure utilized was a cognitive screening test and not as rigorous as those of other studies.
Previous studies have had methodological difficulties [2] . No study to date has investigated both driving and cognition before and after treatment with transdermal fentanyl. This study fills a gap in the literature by using patients as their own controls and by studying driving and cognition before and after treatment with a stable dose of transdermal fentanyl.
Methods
This study was a single-group design with patients acting as their own controls before and after achieving a stable dose of transdermal fentanyl. The study tested the effects of transdermal fentanyl on simulated driving, cognition, and balance. The Institutional Review Board of Thomas Jefferson University approved the study. Patients with chronic nonmalignant pain conditions were recruited from a tertiary care outpatient pain facility associated with an academic medical school. Patients who met inclusion criteria were asked to participate in the study and gave written informed consent. Participants were informed that they could withdraw from the study at any time.
Inclusion and Exclusion Criteria
Participants were patients with chronic nonmalignant pain, from 18-67 years old, taking <15 mg of oral oxycodone per day (i.e., approximately three acetaminophen 325 mg/oxycodone 5 mg tablets), who had valid driver's licenses, who were deemed appropriate for long-acting opiate therapy by their treating physicians, and who were able to complete tests.
Exclusion criteria included the use of benzodiazapines, tizanidine, cyclobenzaprine, carisoprodol, methocarbamol, chlorzoxazone, or metaxalone, or >20 mg per day of lioresal.
Study Design
After obtaining written informed consent, baseline measures of driving simulation, cognition, and psychomotor skills were completed. Patients were also given the Structured Clinical Interview for DSM-IV (SCID) Depression and Dysthymia subscales [9] . Patients taking short-acting opioids prior to the study (maximum of three acetaminophen 325 mg/oxycodone 5 mg tablets per day) continued on the same breakthrough medications as before. Other medications that began prior to the study continued and did not change during the course of the study.
Transdermal fentanyl was titrated over a period of 1 month. Patients received weekly phone calls to monitor pain and side effects. The transdermal fentanyl dose was increased, as tolerated, by 25 mg/hour per week for a period of 4 weeks (maximum dose 125 mg/hour) for adequate pain control. Breakthrough medication at a maximum of three acetaminophen 325 mg/oxycodone 5 mg tablets per day could be used during the titration period. Shortacting opioid doses were converted to oxycodone equivalents if they took vicodin or acetaminophen with codeine. At the end of the fourth week, patients met with their physicians to evaluate the efficacy of treatment. If transdermal fentanyl was well tolerated, the dose was maintained for an additional 4 weeks. At the end of the fourth week of the stabilization period, patients were administered a repeat set of driving simulation, cognition, and balance tests.
Measures

Driving Measures
To evaluate the effect of transdermal fentanyl on driving skills, patients completed several driving tasks in a simulator (Doron L-350, Doron Precision Systems, Inc., Binghampton, NY) before and after stabilization of transdermal fentanyl. The simulator is a console with a car seat, steering wheel, and seat belt. Simulated driving situations are projected on a screen. The simulator records reaction times and errors in braking, steering, speed, and signaling. The simulator was used for four driving tasks: Simple braking reaction time, cue recognition reaction time, destination driving, and evasive action. Simple braking reaction time was measured as the time it took a patient to move their foot from a depressed gas pedal to the brake when two red lights were randomly displayed on the console. Simple braking reaction time scores were computed as an average of the middle 10 values of 14 trials. Cue recognition reaction time was the time it took to brake from a depressed gas pedal when a symbol was displayed on the screen. An average was computed from eight presentations, each subsequently more difficult. Destination driving involved following directions during in-town and highway driving scenarios to arrive at a final destination. The final score was an average of breaking, steering, speed, and signaling errors during each of these scenarios. Evasive action was taking appropriate action in three critical driving situations. The final score was the average time taken for response over the three trials. [10] . Trails consisted of two timed connectthe-dots type tests in which patients were asked to connect sequential letters (Trails A) and alternating letters and numbers (Trails B). Final scores were the time taken to complete each test.
Cognitive Measures
Memory was tested by the Rey Complex Figure Test and Recognition Trial (Rey) [11] and the Weschler Memory Scale-III Spatial Span test (WMS-III) [12] . Visual and constructional memory were tested by the Rey, a test in which participants copy and recall a complex drawing. Immediate recall was tested after 3 minutes and delayed recall was tested after 20 minutes. Recognition recall was accurately identifying parts of the drawing from a set of partial drawings. Visual and spatial memory were tested by the WMS-III. In this task, patients were asked to mimic the order of three-dimensional blocks touched on a board. First, the examiner pointed to a series of blocks on a board and the examinee copied the sequence. The examinee was then asked to copy the sequences in reverse order. Visual sequences became longer as the participant correctly copied each sequence.
Attention was tested with a paper-and-pencil test (d2 Test of Attention) [13] and a computerized task (Conner's Continuous Performance Test II [CPT-II]) [14] . Focus and concentration were tested with the d2 Test of Attention [13] . This is a timed test that requires the examinee to scan each line and cross out target letters and characters and ignore other characters. The examinee was given 20 seconds to complete each line and then had to move to the next line. Concentration and reaction time were tested with the CPT-II [14] . This task consists of letters that flash on a black screen at changing intervals. Patients were required to press the space bar each time they saw a letter, with the exception of one specified letter. The CPT-II takes 15 minutes to administer and measures accuracy and the consistency of attention.
Balance
Balance was tested by a physical therapist. The Berg Balance Test [15] consists of tasks that require patients to demonstrate balance (e.g., standing with eyes closed, standing on one leg). It is a standardized measure that takes 10-15 minutes to complete. A force plate, a flat surface with computerized components that measure bodily sway, measured postural assessment or the patient's ability to stand still while standing. Patients stood still on the platform for 1 minute.
Analyses
Data from this one-group pretest-posttest design were analyzed with SPSS for Windows (version 9; SPSS Inc., Chicago, IL). Descriptive data are presented in Table 1 . Nonparametric statistical analyses were conducted using the Wilcoxon signed rank test to assess differences between the pre-and posttest scores. SPSS uses the Z score as a standard statistic for the Wilcoxon test. The level of statistical significance was set at p < 0.05.
Results
Demographic information can be found in Table  1 . There were 27 patients who met inclusion criteria. One patient could not fill out the tests and was excluded from the study. Three patients dropped out during the transdermal fentanyl titration period due to side effects, including mild sedation (two patients) and itching at the site of the patch (one patient), not requiring treatment. Twenty-three patients completed the study. The final sample was 26% men (N = 6) and 74% women (N = 17), with an average age of 47 years (±9.5 SD; range: 33-67). Diagnoses included degenerative spinal conditions (57%) and neuropathic pain conditions (43%). None of the patients participating in the study met DSM-IV criteria for current clinical depression based on the SCID. Twelve patients took an average equivalent of 12 mg/day of oxycodone prior to beginning the study. Thirteen patients reported taking an average equivalent of 11 mg/day of oxycodone at the end of the study. Transdermal fentanyl doses at the end of the study were as follows: 35% (N = 8) were taking 25 mg/hour, 48% (N = 11) were taking 50mg/hour, and 17% (N = 4) were taking 75mg/hour. Self-reported pain intensity decreased between the baseline visit (mean VAS score: 67) and the stabilization visit (mean VAS score: 53; Z = -2.2, P = 0.02). Table 2 shows the effects of transdermal fentanyl treatment on driving performance. Overall, there were no differences between measures of driving performance before and during treatment with transdermal fentanyl. Reaction time was measured in two exercises-simple breaking reaction time and cue recognition reaction time. No significant differences were found between simple braking reaction times (Z = 0.34, P = 0.74) or cue recognition reaction times (Z = 0.37, P = 0.72) before and during the use of transdermal fentanyl. Destination driving was measured by appropriate breaking, steering, signaling, and speed in two driving scenarios (in-town driving and highway destination driving). No differences in errors were found between in-town destination driving (Z = 1.29, P = 0.20) or highway destination driving (Z = 1.18, P = 0.24) tested before and during the use of the transdermal fentanyl. Additionally, no differences were found between measures of taking evasive action (i.e., driving in critical situations) (Z = 1.06, P = 0.29) prior to and during transdermal fentanyl use. Table 3 shows the results of tests on cognitive performance. There was no decrease in cognitive performance with the use of transdermal fentanyl and, in fact, some measures improved.
Driving Performance
Cognitive Performance
There was no decrease in performance in either Trails A or Trails B. There was no significant difference between scores on the test of visual motor tracking-Trails A (Z = 0.75, P = 0.46) and there was improvement on the test of mental flexibility-Trails B (Z = 2.19, P = 0.03) taken before and during treatment with the transdermal fentanyl.
Tests of visual and constructional memory revealed no differences between spatial sequences (WMS-III; Z = 0.87, P = 0.38) or recognition recall (Rey Recognition; Z = 0.88, P = 0.38) measured before and during treatment with transdermal fentanyl. Improvement was found in both immediate recall (Z = 3.88, P < 0.01) and 20-minute-delayed recall (Z = 2.57, P = 0.01) during transdermal fentanyl use. For concentration, a higher number correct-number errors; for reaction time, lower t-scores; for focus, lower max-min raw score; and for attentiveness, lower t-scores.
There was no decrease in performance on several measures of attention after transdermal fentanyl use. No differences were found in concentration (d2 Test of Attention Concentration Score; Z = 1.34, P = 0.18) or in reaction time (CPT-II Hit Reaction Time; Z = 1.64, P = 0.10) before and during treatment with transdermal fentanyl. Improvements were found in focus (d2 Test of Attention Fluctuation Score; Z = 2.89, P < 0.01) and attentiveness (CPT-II Attentiveness Score; Z = 2.37, P = 0.02) while on the transdermal fentanyl.
Balance
Results of balance tests are found in Table 4 . No significant differences were found in two tests of balance, namely, bodily sway (Z = 0.0, P = 1.0) and the Berg Balance Test (Z = 0.55, P = 0.59), between the testing periods.
Discussion
The results of this study show that driving performance did not change over the course of treatment with transdermal fentanyl. This result is similar to other studies that found few differences in driving performance measures between patients taking opioid medication and healthy controls [2] and patients taking opioids and patients who had experienced cerebrovascular accidents or traumatic brain injuries [6] .
Cognitive performance did not decline on any measure over the treatment period. Rather, a stable dose of transdermal fentanyl was associated with performance improvements in several measures. Other investigators have found improvements in some measures of cognitive performance and suggested that pain may have impeded performance on cognitive tasks [7] . Patients were considered candidates for this study when their treating physician judged them to be appropriate for longacting opiate therapy. Therefore, pain treatment may not have been optimal prior to entry into the study. Pain scores in our sample improved over the course of treatment with transdermal fentanyl. Lorenz et al. [16] studied cognitive functioning in chronic pain patients during administration of acute pain stimuli after 7-14 days of treatment with sustained-release oral morphine and found that cognition improved when pain decreased. Additionally, they concluded that results from studies conducted with patients without pain could not be directly applied to patients with pain.
The results of this study strengthen the findings of previous studies by using a within-subjects design, controlling for patient's pain, cognitive status, driving ability, underlying medical condition, and medication regimen. Additionally, this study controlled for the addition of one longacting opioid before and after testing. Although several patients took anticonvulsants (N = 12) and/or low-dose tricyclic antidepressants (N = 4), doses of those medications did not change throughout the course of the study. Therefore, the primary variable studied was the addition of longacting opioids.
There are limitations to this study. These results should be viewed with some caution, since the sample was small. Lack of statistical significance does not necessarily mean no differences existed, because the study was a pilot study and not powered. However, confidence intervals for the mean differences were computed by estimation through paired sample t-tests. All sample means fell within the 95% confidence intervals computed. Therefore, results revealed that the procedure was such that 95% of the intervals obtained would include the true parameter. Although the study contained a small sample of patients, this number is consistent with the majority of the literature in this area. Finally, driving simulation was tested in this study versus on-the-road driving. This limitation existed due to institutional liability concerning the perception of the potential consequences of taking opioids and driving.
This study does not address the effects of transdermal fentanyl in the time period immediately after the initiation of therapy. Although the literature to date suggests few differences in driving simulation and cognitive performance for patients with nonmalignant pain treated with stable opioids, the amount of time needed to achieve a [17] . Studies of patients with chronic pain conditions taking opioids report the duration of side effects of opioids from 7 days to 6 weeks or longer. The question remains as to whether or not patients have difficulty driving during the initiation of treatment with the transdermal fentanyl. This study did not address doses of opioids higher than 75 mg/hour. However, the results of other studies in which the average dose of opioids was larger are similar to the results of this study in driving simulation tasks [6] and in cognitive performance for patients with nonmalignant pain conditions [2] . Additionally, post-hoc comparisons between individuals taking 50 mg/hour or 75 mg/hour (N = 8) and those taking 25 mg/hour (N = 11) did not reveal significant differences in driving or cognitive measures. Research on driving and cognition that involves the within-subject design and includes larger doses of opioids is also necessary.
Twenty-three out of 26 patients (one patient never completed forms) were able to tolerate the fentanyl patch during the driving study. Three patients dropped out because of mild side effects that did not require any treatment. These side effects all resolved completely upon discontinuation of treatment. All of the side effects were known to be associated with treatment with the fentanyl patch. There were no serious adverse events from the use of the fentanyl patch during the course of this study.
We did not address subsets of patients that may have had individual differences in response to opioids, specifically older individuals and patients taking benzodiazapines. Previous studies have shown that driving skill deteriorates in both of those groups. Research should address this question, since both subsets of patients are commonly seen in pain practices.
Finally, future research should focus on choosing adequate controls, the time course of potential driving and cognitive deficits, different doses of opioids, and subsets of patients who may be more sensitive to the side effects of long-acting opioids and on performance in real driving situations (e.g., on-the-road tests). Clearly, the effects of longacting opioids on driving and cognitive functioning are an important area for future study for physicians, patients, and society. Continued accumulation of research demonstrating the lack of significant differences in driving skills and cognition may enhance the likelihood of funding for these studies.
Conclusion
The addition of transdermal fentanyl to the treatment regimen for patients with chronic nonmalignant pain conditions taking up to 15 mg oral oxycodone equivalent (i.e., approximately three tablets) per day did not negatively affect driving performance, reaction time, or cognition. Future studies in this area are needed and could provide information on making treatment decisions.
